Perturbation of rodent hepatocyte growth control by nongenotoxic hepatocarcinogens: Mechanisms and lack of relevance for human health (review)

Oncology Reports

Volumn 5, Issue 6, 1998, Pages 1319-1327

  Chevalier, Stephan ^a   Roberts, Ruth A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Apoptosis; Cell cycle; DNA synthesis; Human risk assessment; Nongenotoxic carcinogenesis; Peroxisome proliferator; PPAR ; TNF

Indexed keywords

CARCINOGEN; PEROXISOME PROLIFERATOR; SCATTER FACTOR;

APOPTOSIS; ARTICLE; BIOASSAY; CARCINOGENESIS; DNA DAMAGE; DNA SYNTHESIS; FATTY ACID OXIDATION; KUPFFER CELL; LIVER CARCINOGENESIS; LIVER CELL; PEROXISOME; PRIORITY JOURNAL; RISK ASSESSMENT; SPECIES DIFFERENCE; TRANSCRIPTION REGULATION;

EID: 0031715297     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.6.1319     Document Type: Article

References (117)

1. Green S: The search for the molecular mechanisms of non-genocoxic carcinogenesis. Mutat Res 248: 371-374, 1991.
2. Butterworth BE: Non-genotoxic carcinogens in the regulatory environment. Regul Toxicol Pharmacol 9: 244-256, 1989.
3. Ashby J and Tennant R: Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat Res 257: 229-306, 1991.
4. Poland A and Knudson JC: 2.3.7,8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanisms of toxicity. Annu Rev Pharmacol Toxicol 22: 517-554, 1982.
5. Peraino C, Fry RJM and Staffeldt E: Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in the rat by 2-aminofluorene. Cancer Res 31: 1506-1512, 1971.
6. Moody DE, Reddy JK, Lake BG, Popp JA and Reese DH: Peroxisome proliferation and non-genotoxic carcinogenesis: commentary on a symposium. Fundam Appl Toxicol 6: 233-248, 1991.
7. Popp JA, Marsman DS, Cattley RC and Conway JG: Hepatocarcinogenicity and peroxisome proliferation. CUT Activities 9: 1-9, 1989.
8. Ashby J, Brady A, Elcombe CR, Elliot BM, Ishmael J, Odum J, Tugwood JD, Kettle S and Purchase IFH: Mechanistically-based human hazard assessment of peroxisome-proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol 13: S1-S117, 1994.
9. Fears R: Drug treatment of hyperlipidaemia. Drugs Today 20: 257-294, 1984.
10. Foxworthy PS and Eacho PI: Effect of the peroxisome proliferator LY1711883 on triglyceride accumulation in rats fed a fat free diet. Biochem Pharmacol 42: 1487-1491, 1991.
11. Tucker MJ and Orton TC: Comparative Toxicology of Hypolipidaemic Fibrates. Taylor & Francis, London, 1992.
12. Reddy JK and Lalwani ND: Carcinogenesis by hepatic peroxisome proliferators. Evaluation of the risk of hypolidaemic drugs and industrial plasticizers to humans. Crit Rev Toxicol 12: 1-58, 1983.
13. Reddy JK, Rao MS, Azarnoff DL and Sell S: Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator Wy-14,643 in rat and mouse liver. Cancer Res 39: 152-160, 1979.
14. Cattley R, De Luca J, Elcombe CR, Fenner-Crisp P, Lake B, Marsman D, Pastoor T, Robinson D, Schwetz B, Tugwood J and Wahli W: Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol 27: 47-60, 1998.
15. Hasmall SC and Roberts RA: Hepatic ploidy, nucelarity and distribution of DNA synthesis: a comparison of non-genotoxic hepatocarcinogens with non-carcinogenic liver mitogens. Toxicol Appl Pharmacol 144: 287-293, 1997.
16. Bursch W, Oberhammer F and Schulte-Hermann R: Cell death by apoptosis and its protective role against disease. Trends Physiol Sci 13: 245-251, 1992.
17. Goldsworthy TL, Conolly RB and Fransson-Steen R: Apoptosis and cancer risk assessment. Mutat Res 365: 71-90, 1996.
18. Roberts RA, Hickman JA, Nebert DW, Richburg JH and Goldsworthy TL: Perturbation of the mitosis/apoptosis balance: a fundamental mechanism in toxicology. Symposium overview. Fundam Appl Toxicol 38: 107-115, 1997.
19. Issemann I and Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650, 1990.
20. Braissant O, Foufelle F, Scotto C, Dauca M and Wahli W: Differential expression of peroxisome-proliferator activated receptors (PPARs): tissue distribution of PPAR-alpha, beta and gamma in the adult rat. Endocrinology 137: 354-366, 1996.
21. Lee SS-T, Pineau T, Drago J, Lee EJ, Owens JO, Kroetz DL, Fernandez-Salguero PM, Westphal H and Gonzalez FJ: Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleitrophic effects of peroxisome proliferators. Mol Cell Biol 15: 3012-3022, 1995.
22. Gonzalez FJ: Recent update on the PPAR alpha-null mouse. Biochimie 79: 139-144, 1997.
23. Auwerx J: Regulation of gene expression by fatty acids and fibric acid derivatives: an integrative role for PPARs. Horm Res 38: 269-277, 1992.
24. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL and Green S: The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11: 433-439, 1992.
25. Melnick RL, Kohn MC and Portier CJ: Implications for risk assessment of suggested non-genotoxic mechanisms of chemical carcinogenesis. Environ Health Perspect 104: 123-134, 1996.
26. Fausto N, Laird AD and Webber AM: Liver regeneration 2: role of growth factors and cytokines in hepatic regeneration. FASEB J 10: 1527-1536, 1996.
27. Taub R: Liver regeneration 4: transcriptional control of liver regeneration. FASEB J 10: 413-427, 1996.
28. Block GD, Locker J, Bowen WC, Peterson BE, Katyal S, Strom SC, Riley T, Howard TA and Michalopoulus GK: Population expansion, clonel growth and specific differentiation patterns in primary culture of hepatocytes induced by HGF/SF, EGF and TCF-alpha in a chemically defined medium (HGM). J Cell Biol 132: 1133-1149, 1996.
29. Coni P, Simbula G, Carceren de Prati A, Menegazzi M, Suzuki H, Sarma DSR, Ledda-Columbano GM and Columbano A: Differences in the steady state levels of c-fos, c-jun and c-myc messenger RNA during mitogen-induced liver growth and compensatory regeneration. Hepatology 17: 1109-1116, 1993.
30. Columbano A and Shinozuka H: Liver regeneration 8: liver regeneration versus direct hyperplasia. FASEB J 10: 1118-1128, 1996.
31. Roberts RA, Soames AR, Gill JH, James NH and Wheeldon EB: Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different discrete hepatocyte populations, Carcinogenesis 16: 1693-1698, 1995.
32. James NH and Roberts RA: Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than with suppression of apoptosis. Carcinogenesis 17: 1623-1632, 1996.
33. Pardce AB: G1 events and the regulation of cell proliferation. Science 246: 603-609, 1989.
34. Michalopoulus GK and De Frances MC: Liver regeneration. Science 276: 60-66, 1997.
35. Lu XP, Kosh KS, Lew DJ, Dolic V, Pines J, Reed SI, Hunter T and Leffert HL: Induction of cyclin mRNA and cyclin-associated histone H1 kinase during liver regeneration. J Biol Chem 267: 2841-2844, 1992.
36. Loyer P, Ilyin G, Cariou S, Glaise D, Corlu A and Guguen-Guillouzo C: Progression through G1 and S phases of adult rat hepatocytes. Prog Cell Cycle Res 2: 37-47, 1996.
37. Loyer P, Glaise D, Cariou S, Baffet G, Meijer L and Guguen-Guillouzo C: Expression and activation of CDKs (1 and 2) and cyclins in cell cycle progression during liver regeneration. J Biol Chem 269: 2491-2500, 1994.
38. Albrecht JH, Hu MY and Cerra FB: Distinct patterns of cyclin D1 regulation in models of liver regeneration and human liver. Biochem Biophys Res Commun 209: 648-655, 1995.
39. Albrecht JH, Poon RYC, Ahonen CL, Rieland BM, Deng C and Crary GS: Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating rat liver. Oncogene 16: 2141-2150, 1998.
40. Kato A, Ota S, Bamba H, Wong RM, Ohmura E, Imai Y and Matzuka F: Regulation of cyclin D dependent kinase activity in rat liver regeneration. Biochem Biophys Res Commun 245: 70-74, 1998.
41. Wu H, Wade M, Krall L, Grisham J, Xiong Y and van Dyke T: Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression postnatal liver development, and regeneration. Genes Dev 10: 245-260, 1996.
42. Loyer P, Cariou S, Glaise D, Bilodeau M, Baffet G and Gugeun-Guillouzo C: Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. J Biol Chem 271: 11484-11492, 1996.
43. Ledwith BJ, Johnson TE, Wagner LK, Pauley CJ, Manam S, Galloway SM and Nichols WW: Growth regulation by peroxisome proliferators: opposing activities in early and late G1. Cancer Res 56: 3257-3264, 1996.
44. Goldsworthy TL, Goldsworthy SM, Sprankle CS and Butterworth BE: Expression of myc, fos and Ha-ras associated with chemically induced cell proliferation in the rat liver. Cell Prolif 27: 269-278, 1994.
45. Holden PR, Soames AE, Foster JR, Tittensor S, Hasmall SC, Elcombe CR, Tug wood JD and Odum J: Differences in S-phase and immediate-early gene expression during compound induced liver growth and compensatory regeneration in the rat. Hum Exp Toxicol 16: 52, 1997.
46. Hasmall SC, Pyrah ITG and Roberts RA: Expression of the immediate early genes c-fos, c-jun and c-myc: a comparison in rats of non-genotoxic hepatocarcinogens with non-carcinogenic liver mitogens. Fundam Appl Toxicol 40: 129-137, 1997.
47. Gill JH, Dive C and Roberts RA: The rodent non-genotoxic hepatocarcinogen, nafenopin suppresses apoptosis preferentially in non-cycling hepatocytes but also elevates CDK4, a cell cycle progression factor. Carcinogenesis (In press).
48. Rininger JA, Goldsworthy TL and Babish JG: Time-course comparison of cell cycle protein expression following partial hepatectomy and Wy-14,643-induced hepatic proliferation in F344 rats. Carcinogenesis 18: 935-941, 1997.
49. Rininger JA, Stoffregen DE and Babish JG: Murine hepatic p53, Rb and CDK inhibitory protein expression following following acute 2,4,7,8-tetracchlorodibenzo-p-dioxin (TCDD) exposure. Chemosphere 34: 1557-1568, 1997.
50. Melnick RL: Does chemically induced hepatocyte proliferation predict liver carcinogenesis? FASEB J 6: 2698-2706, 1992.
51. Ames BN and Gold LS: Too many rodent carcinogens: mitogenesis increases mutagenesis. Science 249: 970-971, 1990.
52. Ward JM, Hagiwara A, Andersen LM, Lindsey K and Diwan BA: The chronic hepatic or renal toxicity of di(2-ethylhexyl)phthalate, acetaminophen, sodium barbital and phenobarbital in male B6C3F1 mice: autoradiographic, immunohistochemical, and biochemical evidence for levels of DNA synthesis not associated with carcinogenesis or tumour promotion. Toxicol Appl Pharmacol 96: 494-506, 1988.
53. National Toxicology Program: Toxicology and carcinogenesis studies of 1,4-dichlorobenzene (CAS No. 106-46-7) in F344/n rats and B6C3F1 mice. NTP TR 217.NIH. Publication No. 87-2575, 1997.
54. Eldridge SR, Goldsworthy TL, Popp JA and Butterworth BE: Mitogenic stimulation of hepatocellular proliferation in rodents following 1,4-dichlorobenzene administration. Carcinogenesis 13: 409-415, 1992.
55. Odum J, Foster JR, Hasmall SC, Tittensor S, Soames AR and Elcombe CR: Markers of non-genotoxic carcinogenesis: 2.F344 rat liver. Hum Exp Toxicol 16: 56, 1997.
56. National Toxicology Program: Carcinosenesis bioassay of di (ethylhexyl)phthalate (CAS No. 117-81-7) in F344 rats and B6C3F1 mice (feed study). NTP TR 217.NIH. Publication No. 82-1773, 1982.
57. Brodsky WY and Uryvaeva IV: Cell ploidy: its relation to tissue growth and function. Int Rev Cytol 50: 275-332, 1977.
58. Schulte-Hermann R: Induction of liver growth by xenobiotic compounds and other stimuli. Crit Rev Toxicol 4: 97-138, 1974.
59. Styles JA, Kelly M and Elcombe CR: A cytological comparison between regeneration, hyperplasia and early neoplasia in the rat liver. Carcinogenesis 8: 391-399, 1987.
60. Styles JA, Kelly M, Pritchard NR and Elcombe CR: A species comparison of acute hyperplasia induced by the peroxisome proliferator methylclofenapate: involvement of the binucleated hepatcyte. Carcinogenesis 9: 1647-1655, 1988.
61. Millar RT, Shah RS, Cattley RC and Popp JA: The peroxisome proliferators WY-14,643 and methylclofenapate induce hepatocyte ploidy alterations and ploidy-specific DNA synthesis in F344 rats. Toxicol Appl Pharmacol 138: 317-323, 1996.
62. Lalwani ND, Dethloff LA, Haskins JR, Robertson DG and De La Iglesia FA: Increased nuclear ploidy, not cell proliferation, is sustained in the peroxisole proliferator-treated rat liver. Toxicol Pathol 25: 165-176, 1997.
63. Bayly AC, Roberts RA and Dive C: Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator, nafenopin. J Cell Biol 125: 197-203, 1994.
64. Oberhammer FA and Qin HM: Effect of three tumour promoters on the stability of hepatocyte cultures and apoptosis after transforming growth factor-beta 1. Carcinosenesis 16: 1363-1371, 1995.
65. Cunningham ML, Soliman MS, Badr MZ and Mathews HB: Rotenone, an anticarcinogen, inhibits cellular proliferation but not peroxisome proliferation in mouse liver. Cancer Lett 95: 93-97, 1995.
66. Bursch W, Dusterberg B and Schulte-Hermann R: Growth, regression and cell death in rat liver as related to tissue levels of the hepatomitogen cyproterone acetate. Arch Toxicol 59: 221-227, 1986.
67. Wyllie AH: Apoptosis (The Frank Rose Memorial Lecture). Br J Cancer 67: 205-208, 1993.
68. Alison MR and Sarraf CE: Apoptosis: regulation and relevance to toxicology. Hum Exp Toxicol 14: 234-247, 1995.
69. Gill JH, Roberts RA and Dive C: The non-genotoxic hepatocarcinogen nafnopin suppresses rodent hepatocyte apoptosis induced by TGFβ1, DNA damage and FAS. Carcinogenesis 19: 299-304, 1998.
70. Tugwood JD, Aldridge TC, Lambe KL, MacDonald N and Woodyatt NJ; PPARs: structures and function. In: Peroxisomes: Biology and Role in Toxicology and Disease. Reddy JK, Suga T, Mannaerts GP, Lazarow PB and Subramani S (eds.) The New York Academy of Sciences, New York, pp252-265, 1996.
71. Holden PR and Tugwood JD: Peroxisome proliferator activated receptor alpha and its involvement in cancer and species differences. J Mol Endocrinol (In press).
72. Stolz C, Vachon M, Trottier E, Dubois S, Paquet Y and Anderson A: The CYP2B2 phenobarbitol response unit contains an accessory factor element and a putative glucocorticoid response element essential for conferring maximal phenobarbital responsiveness. J Biol Chem 273: 8528-8536, 1998.
73. Peters JM, Cattley RC and Gonzalez FJ: Role of PPAR alpha in the mechanism of action of the non-genotoxic carcinogen and peroxisome proliferator, Wy-14,643. Carcinogenesis 18: 2029-2033, 1997.
74. Myers KA, Lambe K, Aldridgc TC, MacDonald N and Tugwood JD: Amino acids in both the DNA binding and ligand binding domains influence the transcriptional activity of the human peroxisome proliferator acivated receptor alpha. Biomed Biophys Res Commun 239: 522-526, 1997.
75. Gonzalez F: The role of peroxisome proliferator activated receptor alpha in peroxisome proliferation, physiological homeostasis and chemical carcinogenesis. In: Dietary Fat and Cancer. AICR (ed.) Plenum Press. New York, pp109-125, 1997.
76. Issemann I, Prince RA, Tugwood JD and Green S: The peroxisome proliferator-activated receptor: retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol 11: 37-47, 1993.
77. Aldridge TC, Tugwood JD and Green S: Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription. Biochem J 306: 473-479, 1995.
78. Yan ZH, Kaam WG, Staudinger JL, Mcdvedev A, Ghanayem BI and Jetten AM: Regulation of PPAR-alpha induced trancription by the nuclear orphan receptor TAK1/TR4. J Biol Chem 273: 10948-10957, 1998.
79. Nishiyama C, Hi R, Osada S and Osumi T: Functional interactions between nuclear receptors recognising a common sequence element, the direct repeat motif spaced by one nucleotide (DR-1). J Biochem 123: 1174-1179, 1998.
80. Yamada Y, Kirillova I, Peschon JJ and Fausto N: Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lackina type I tumor necrosis factor receptor. Proc Natl Acad Sci USA 94: 1441-1446, 1997.
81. Yamada Y and Fausto N: Deficient liver regeneration after carbon tetrachloride injury in mice lacking type 1 but not type 2 tumor necrosis factor receptor. Am J Pathol 152: 1577-1581, 1998.
82. Cressman D, Diamond R and Taub R: Rapid activation of the Stat3 trancription complex in liver regeneration. Hepatology 21: 1443-1449, 1995.
83. Bojes HK and Thurman RG: Peroxisome proliferators activate kupffer cells in vivo. Cancer Res 56: 1-4, 1996.
84. Rose ML, Germolec D, Schoonhoven R and Thurman RG: Kupffer cells are causally responsible for the mitogenic effect of peroxisome proliferators. Carcinogenesis 18: 1453-1456, 1997.
85. Beyer HS and Theologides A: Tumor necrosis factor-alpha is a direct hepatocyte mitogen in the rat. Biochem Mol Biol Int 29: 1-4, 1993.
86. Rolfe M, James NH and Roberts RA: Tumour necrosis factor alpha (TNF-alpha) suppreses apoptosis and induces S-phase in rodent hepatocytes: a mediator of the hepatocarcinogenicity of peroxisome proliferators? Carcinogenesis 18: 2277-2280, 1997.
87. Akerman P, Cote P, Yang S, McClain C, Nelson S, Bagby G and Diehl AM: Antibodies to tumor necrosis factor-alpha inhibit liver reseneration after partial hepatectomy. Am J Physiol 263: 579-585, 1992.
88. Bojes HK, Germolec DR, Simeonova P, Bruccolrei A, Schoonhoven R, Luster MI and Thurman RG: Antibodies to tumor necrosis factor-alpha prevent increases in cell replication in liver due to the potent peroxisome proliferator WY-14,643. Carcinogenesis 18: 669-674, 1997.
89. Menegazzi M, Carcereri-De Prati A, Shinozuka H, Pibiri M, Piga R, Columbano A and Ledda-Columbano GM: Liver cell proliferation induced by nafenopin and cyproterone acetate is not associated with increases in activation of transcription factors NF-κB and AP-1 or with expression of tumor necrosis factor-alpha. Hepatoloay 25: 585-592, 1997.
90. Beg AA, Sha WC, Bronson RT, Ghosh S and Baltimore D: Embryonic lethality and liver degeneration in mice lacking the RcIA component of NF-kappa B. Nature 376: 167-170, 1995.
91. Li Y, Leung LK, Glauert HP and Spear BT: Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-kappa B activity. Carcinogenesis 17: 2305-2309, 1996.
92. Rusyn I, Tsukamoto H and Thurman RG: Wy-14,643 rapidly activates nuclear factor KB in Kupffer cells before hepatocyte. Carcinogenesis 19: 1217-1222, 1998.
93. Li Y, Leung LK, Spear BT and Glauert HP: Activation of hepatic NFκB by phenobarbital in rats. Biochem Biophys Res Commun 229: 982-989, 1996.
94. Bien F and Lhuguenot JC: Toxicity of peroxisome proliferators. Biochimie 75: 263-268, 1993.
95. Lake BG, Evans JG, Gray TJB, Korosi SA and North CJ: Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset. Toxicol Appl Pharmacol 99: 148-160, 1989.
96. Price RJ, Evans JG and Lake BG: Comparison of the effects of nafenopin on hepatic peroxisome proliferation and replicative DNA synthesis in the rat and syrian hamster. Fd Chem Toxic 30: 937-944, 1992.
97. Perrone CE, Shao L and Williams CM: Effect of rodent hepatocarcinogenenic peroxisome proliferators on fatty acyl CoA oxidase, DNA synthesis and apoptosis in cultured human and rat hepatocytes. Toxicol Appl Pharmacol 150: 277-286, 1998.
98. Elcombe CR and Mitcheil A: Peroxisome proliferation due to di(2-ethyl)phthalate: species differences and possible mechanisms. Environ Health Perspect 70: 211-219, 1986.
99. Bentley P, Calder I, Elcombe E, Grasso P, Stringer D and Wiegand HJ: Hepatic peroxisome proliferation in rodents and its significance to humans. Fd Chem Toxic 31: 857-907, 1993.
100. Williams GM and Perrone C: Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens. In: Peroxisomes: Biology and Role in Toxicology and Disease. Reddy JK, Suga T, Mannaerts GP, Lazarow PB and Subramani S (eds.) The New York Academy of Sciences, New York, pp554-572, 1995.
101. Schoonjans K, Staels B and Auwerx J: Role of the peroxisome proliferator activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37: 905-925, 1996.
102. Hanefeld M, Hemmer C and Kadner E: relationship between morphological changes and lipid lowering action of p-chlorophenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis 46: 239-246, 1983.
103. Watanabe T, Horie S, Yamada J, Isaji M, Nishigaki T, Naito J and Suga T: Species differences in the effects of bezafibrate, a hypolipidaemic agent, on hepatic peroxisome associated enzymes. Biochem Pharmacol 38: 430-437, 1989.
104. Arends MJ, McGregor AJ and Wyllie A: Apoptosis is inversely related to necrosis and determines net growth rate in tumours bearing constitutively expressed myc, ras and HPV oncogenes. Am J Pathol 144: 1047-1057, 1994.
105. Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G and Wahli W: Positive regulation of the peroxisomal-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol Cell 77: 67-76, 1993.
106. Green S: Receptor-mediated mechanisms of peroxisome proliferators. Biochem Pharmacol 43: 393-401, 1992.
107. Green S, Tugwood JD and Issemann I: The molecular mechanism of peroxisome proliferator action: a model for species differences and mechanistic risk assessment. Toxicol Lett 64/65: 131-139, 1992.
108. Roberts RA, James NH, Woodyatt N, MacDonald N and Tugwood J: Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPARα). Carcinogenesis 19: 43-48, 1998.
109. Palmer CNA, Hsu M-H, Griffin KJ, Raucy JL and Johnson EF: Peroxisome proliferator activated receptor alpha expression in human liver. Mol Pharmacol 53: 14-22, 1998.
110. Sher T, Yi HF, McBride W and Gonzalez FJ: cDNA cloning, chromosomal mapping and functional characterisation of the human peroxisome proliferator-activated receptor. Biochemistry 32: 5598-5604, 1993.
111. Mukherjee R, Jow L, Noonan D and McDonnell DP: Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem 51: 157-166, 1994.
112. Tugwood JD, Holden PR, James NH, Prince RA and Roberts RA: A PPAR-alpha cDNA cloned from guinea pig liver encodes a protein with similar properties to the mouse PPARα: implications for species differences in response to peroxisome proliferators. Arch Toxicol 72: 169-177, 1998.
113. Bell AR, Savory R, Horley NJ, Choudhury AI, Dickins M, Gray TJB, Salter AM and Bell DR: Molecular basis of non-responsiveness to peroxisome proliferators: the guinea pig PPAR-alpha in functional and mediates peroxisome proliferator-induced hypolipidaemia. Biochem J 332: 689-693, 1998.
114. Diffley FJX: Once and only once upon a time: specifying and resulating origins of DNA replication in eukaryotic cells. Genes Dev 10: 2819-2830, 1986.
115. Chevalier S and Blow JJ: Cell cycle control of replication initiation in eukaryotes. Curr Opin Cell Biol 8: 815-821, 1996.
116. Sherr CJ and Roberts JM: Inhibitors of mammalian G3 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
117. Sherr CJ: Mammalian G1 cyclins. Cell 73: 1059-1065, 1993.